← All indications
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Drugs by status
Approved for this indication (5)
Phase 4 trials (64)
- urea
- tenofovir
- ledipasvir
- carvedilol
- gimeracil
- entecavir
- mycophenolate
- xihuang
- azathioprine
- thymalfasin
- tacrolimus
- interferon alpha-2b
- cidan
- vitamin d3
- adefovir dipivoxil
- desflurane
- sintilimab
- propranolol
- lamivudine
- sodium chloride
- sevoflurane
- cabozantinib
- tegafur
- lapatinib
- sofosbuvir
- epirubicin
- sufentanil
- tirelizumab
- recombinant human adenovirus type 5
- norepinephrine
- +34 more
Phase 3 trials (120)
- pravastatin
- chlorotrianisene
- carboplatin
- ql1706
- idarubicin
- fatty acid
- arginine
- orantinib
- enoxaparin
- thalidomide
- shr-8068
- elbasvir
- brivanib alaninate
- ipilimumab
- daclatasvir
- oxaliplatin
- Raltitrexed
- batabulin
- prednisone
- grazoprevir
- penpulimab
- pirarubicin
- adebrelimab
- sulfur hexafluoride lipid-type a microspheres
- pi-88
- styrene maleic acid neocarzinostatin
- mitomycin
- allogeneic natural killer cells
- aprepitant
- cisplatin
- +90 more
Phase 2 trials (331)
- p03277
- trx-818
- gi-4000
- nogapendekin alfa inbakicept
- ect204 t cells
- endostatin
- ga68-dolacga
- b7-h3 car-t
- tigatuzumab
- mogamulizumab
- gi-6207
- oprozomib
- galunisertib
- bgb-a1217
- fludarabine
- folfirinox
- relatlimab
- ro5137382
- apl-101
- cediranib
- Amcasertib
- tomivosertib
- ly2181308
- etbx-011
- acetylcysteine
- crcl-allovax
- js207
- js006
- belimumab
- tti-101
- +301 more
Phase 1 trials (184)
- tegar t cells
- incb062079
- il-2 expressing salmonella typhimurium
- itacitinib
- np137
- c-tcr055
- mm-141
- ro7119929
- zw251
- ast-201
- et1402l1-cart cells
- liver nk cell
- imiquimod
- naptumomab estafenatox
- rsifn-co
- autologous dendritic cells loaded with autologous tumor lysate
- zsp1241
- rd-cy7
- umbilical cord blood derived mak immune cells
- cd19 car-t cells
- gpc3 and/or tgfβ targeting car-t cells
- azd-1480
- cd147-car t cells
- wgc0201
- dusigitumab
- selinexor
- gen2
- yang yin fu zheng jie du
- vmd-928
- navitoclax
- +154 more
Other trials (47)
- lactobacillus delbrueckii
- tenofovir alafenamide
- ginsenoside rg3
- polysaccharide mgn3
- vic-1911
- Lentinula edodes
- iminodiacetic acid
- bay94-9392
- graviola
- anti-gpc3-irdye800cw
- technetium tc-99m sulfur colloid kit
- gadopenteate dimeglumine
- sz003
- enterococcus faecium
- agen2034
- bcma-pd1-cart cell
- chtnt-1
- ulinastatin
- aminoleban
- gadobenate
- methylprednisolone
- mebendazole
- cm310
- autologous rak cells
- car-cld18 t cells
- agen1181
- phytonadione
- rep 2139
- dc vaccine
- ropivacaine
- +17 more
Organizations
Organization Involved with Phase 4 Indications (62)
- People's Liberation Army of China
- Nanjing University
- Taipei Medical University
- University of Strasbourg
- Peking University
- Xiamen Traditional Chinese Medicine Co., Ltd.
- Beijing Cancer Hosptial
- Capital Medical University
- Second Military Medical University
- Sungkyunkwan University
- University of Toronto
- Tanta University
- Ditmanson Medical Foundation
- Fujian Mengchao Hepatobiliary Hospital
- Tainan Municipal Hospital
- Qidong Gaitianli Medicines Co., Ltd
- Tokyo Medical and Dental University
- Kaohsiung Medical University
- Government of Taiwan
- Medical College of Wisconsin
- Chimei Medical Center
- Harvard University
- Guerbet
- University of Florida
- Taipei Veteran General hospital
- Baylor University
- Nutricia
- Icahn School of Medicine at Mount Sinai
- Huazhong University of Science and Technology
- University of Vienna
- +32 more
Organization Involved with Phase 3 Indications (183)
- Roche
- Wenzhou Medical University
- University of South China
- Nantong University
- Accuray Incorporated
- Yancheng Third People's Hospital
- German Federal Ministry of Education and Research
- Gilead Sciences
- Green Cross Corporation
- Ono Pharmaceuticals
- Anhui College of Traditional Chinese Medicine
- Tata Memorial Hospital
- Tigermed Consulting Co., Ltd
- University of Bonn
- Fondazione Giovanni Pascale
- Badalona Hospital Germans Trias i Pujol
- Leo Pharma
- Evangelischen Diakoniekrankenhaus
- Foshan First People's Hospital
- Jiangsu University
- AbbVie
- Chongqing Medical University
- SillaJen, Inc.
- Fujian Medical University
- Tengzhou Central People's Hospital
- Newcastle University
- Zhejiang University
- Clinica Universidad de Navarra
- Xinxiang Medical University
- Guangzhou Medical University
- +153 more
Organization Involved with Phase 2 Indications (266)
- Eastern Cooperative Oncology Group
- Southeast University
- Hacettepe University
- Monofeiya university
- Zollernalbklinikum Balingen
- CHU Mont-Godinne
- Antengene Corporation
- Bumrungrad International Hospital
- Catholic University of Korea
- CureTech Ltd
- Federation Francophone de Cancerologie Digestive
- Philipps University of Marburg
- University of Copenhagen
- Crolll Gmbh
- RedHill Biopharma
- University of Padova
- Apogee Biotechnology Corporation
- National Cancer Center, Korea
- North Central Cancer Treatment Group
- Idun Pharmaceuticals
- Alphamab Co., Ltd.
- Pharmexa A/S
- Takeda
- Fibrolamellar Cancer Foundation
- Wyeth
- University of Zurich
- Pakistan Army
- Mayo Clinic
- Chulalongkorn University
- Astellas
- +236 more
Organization Involved with Phase 1 Indications (86)
- Verlyx Pharma Inc
- Nektar Therapeutics
- University of Gothenburg
- Lotte & John Hecht Memorial Foundation
- Novotech
- Envita Medical Centers
- Curegenix Inc.
- Shin Kong Wu Ho-Su Memorial Hospital
- Accord Research
- Tvardi Therapeutics, Incorporated
- Sharp Clinical Oncology Research
- Sirnaomics
- Department of Health and Human Services
- Shijiazhuang Pharma Group (CSPC)
- Surface Oncology
- University of Kansas
- Chugai
- Florida Department of Health
- Makati Medical Center
- Manila Doctors Hospital
- NeoTX Therapeutics Ltd.
- Chipscreen Biosciences, Ltd.
- 3D Medicines
- Biogen
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Cellular Biomedicine Group Ltd.
- Therapure Biopharma
- Institut National de la Santé Et de la Recherche Médicale, France
- Mereo BioPharma
- Blueprint Medicines Corporation
- +56 more
Organization Involved with Other Experimental Indications (18)
- Kochi University
- Caladrius Biosciences
- Rouen Normandy University
- Institute of hepatobiliary surgery,Southwest Hospital
- Beijing Insight Science & Technology Co. Ltd.
- Nanchang University
- The First People's Hospital of Yunan Province
- MDS Pharma
- Bracco
- Vietnamese Military
- Cancer Hospital of Yunnan provinceal
- xCures
- Charles Drew University
- University of Louisville
- Boston Scientific Corporation
- Loma Linda University
- Cancer Commons
- Institute of Liver and Biliary Sciences, India